NOA-21 (AMPLIFY-NEOVAC)

AMPLIFY-NEOVAC: A Randomized, 3-Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1-vac Combined with an Immune Checkpoint Inhibitor Targeting Programmed Death-ligand 1 in Isocitrate Dehydrogenase 1 Mutant Gliomas